The gene and cell therapy sectors continue dynamic shifts with new clinical data and strategic realignments. AstraZeneca’s gefurulimab showed positive phase III results in generalized myasthenia gravis, supporting advancement. Neurogene and Taysha are progressing Rett syndrome gene therapies, with US regulatory approval secured for key trial designs. Adicet Bio is pivoting to autoimmune disease therapies, discontinuing certain assets and reducing workforce. Meanwhile, Roche announced termination of several early-phase cancer and obesity drug programs, including a Carmot obesity asset, restructuring its pipeline to focus on prioritized projects. These movements reflect ongoing prioritization in the rapidly evolving advanced therapy space.